$5.62
6.34% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US60853G1067
Symbol
MOLN
Sector
Industry

Molecular Partners AG - ADR Stock News

Neutral
GlobeNewsWire
19 days ago
Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only
Neutral
GlobeNewsWire
26 days ago
Radio-DARPin Therapy (RDT) Candidate MP0712 supported by in vivo data presented at the European Association of Nuclear Medicine (EANM) Congress; first-in-human start and initial clinical data expected in 2025
Neutral
GlobeNewsWire
about one month ago
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the pricing of an underwritten offering in the ...
Neutral
GlobeNewsWire
about one month ago
Dose-dependent efficacy observed with favorable safety profile Attractive tumor to kidney ratios shown in biodistribution studies Picomolar affinity and high specificity for DLL3 as precision attributes for alpha radiation therapy Molecular Partners and Orano Med preparing for clinical entry in 2025  ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, Oct. 22, 2024 (GLOBE NEWSWIRE) -- A...
Neutral
GlobeNewsWire
about one month ago
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) --  Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the strengthening of a previously announced co...
Neutral
GlobeNewsWire
about 2 months ago
Preclinical proof-of-concept data supports CD3 Switch-DARPin platform for T cell engagers with enhanced function in solid tumors Biomarker data on completed phase 1 study of MP0317 (FAP x CD40) shows intended and marked tumor microenvironment modulation ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical...
Neutral
GlobeNewsWire
2 months ago
First RDT candidate MP0712 shows low kidney accumulation and high tumor uptake in preclinical models MP0712 treatment leads to strong tumor growth inhibition with a good safety profile in vivo ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-buil...
Neutral
GlobeNewsWire
3 months ago
First Radio-DARPin Therapy (RDT) candidate MP0712 nominated; supporting preclinical package presented at SNMMI; initial clinical data expected in 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today